Tirzepatide and semaglutide are both incretin-based medications, but they work differently. Compare their mechanism, weight loss study results, side effects, dosing, cost and other important differences.
Tirzepatide and semaglutide belong to the broader family of incretin-based therapies, but they are not identical medications. One of their most important differences is the number of hormone receptors they target.
Dual GIP + GLP-1 receptor agonist
GLP-1 receptor agonist
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Drug class | Dual GIP / GLP-1 receptor agonist | GLP-1 receptor agonist |
| Hormone targets | GIP + GLP-1 | GLP-1 |
| Example brands | Mounjaro®, Zepbound® | Ozempic®, Wegovy® |
| Dosing | Product-specific | Product-specific |
| Side effects | Can include gastrointestinal effects | Can include gastrointestinal effects |
| Cost | Varies by product and coverage | Varies by product and coverage |
Tirzepatide vs Semaglutide differ primarily in the hormonal pathways they target. Both medications interact with pathways involved in glucose regulation, appetite and digestion. Semaglutide targets the GLP-1 receptor, while tirzepatide has activity at both GIP and GLP-1 receptors.
Tirzepatide activates both GIP and GLP-1 receptors. These pathways are involved in glucose regulation, appetite and other metabolic processes.
Semaglutide mimics GLP-1 activity by stimulating the GLP-1 receptor. This pathway is involved in appetite, glucose regulation and digestion.
Tirzepatide vs Semaglutide for weight loss has been examined in clinical research, including direct head-to-head evidence. These studies help show why incretin-based therapies have become an important area of obesity treatment, although results should always be interpreted according to the population studied, treatment duration, dose and specific products evaluated.
In SURMOUNT-5, participants receiving tirzepatide had an estimated average body-weight reduction of 20.2% at 72 weeks.
In the same head-to-head trial, participants receiving semaglutide had an estimated average body-weight reduction of 13.7% at 72 weeks.
SURMOUNT-5 was a 72-week randomized clinical trial involving adults with obesity but without type 2 diabetes. Clinical trial findings describe outcomes in the study population and do not predict an individual person's results.
SURMOUNT-5 provides direct head-to-head evidence for tirzepatide vs semaglutide. At 72 weeks, both treatment groups experienced substantial average weight reduction, with a greater reduction observed with tirzepatide in this study. These findings highlight the potential of incretin-based therapies in obesity treatment, while individual results, suitability and treatment decisions depend on clinical circumstances and should be discussed with a qualified healthcare professional.
Take our quick educational quiz to explore GLP-1 topics and questions you may want to discuss with a healthcare professional.
Tirzepatide and semaglutide can cause similar side effects, particularly gastrointestinal symptoms. The exact risks, warnings and frequency of side effects can vary by medication, dose and individual patient factors.
These medications have important contraindications, warnings and precautions that are not fully summarized here. A healthcare professional should review a patient's medical history, current medications and individual risk factors before treatment.
Side effects may be more noticeable when treatment begins or after a dose increase. Individual experiences vary, so treatment decisions and dose adjustments should be discussed with a qualified healthcare professional.
Tirzepatide vs Semaglutide dosing can differ because products containing these medications may follow different dosing schedules and dose-escalation plans. The appropriate regimen depends on the specific medication, indication and individual treatment plan.
Product-specific dosing
Product-specific dosing
Dosing should follow the prescribing information for the specific product and guidance from a qualified healthcare professional. Different brands or formulations should not be assumed to use interchangeable dosing schedules.
The amount a patient pays for tirzepatide or semaglutide can vary considerably. The final out-of-pocket cost depends on the specific brand, insurance coverage, indication, pharmacy and available savings programs.
Mounjaro® / Zepbound®
Ozempic® / Wegovy®
List prices do not necessarily reflect what an individual patient will pay. Coverage, eligibility requirements and savings programs can change over time, so current information should be confirmed with the relevant insurer, pharmacy or program provider.
When comparing Tirzepatide vs Semaglutide, both are incretin-based medications, but they are not the same drug. One of the main differences is their mechanism of action: tirzepatide targets both GIP and GLP-1 receptors, while semaglutide targets the GLP-1 receptor. Their approved uses, dosing, study results, side effects and costs can also differ by product.
This comparison is for general educational purposes and does not replace advice from a qualified healthcare professional.
These Tirzepatide vs Semaglutide FAQs cover common questions about how the two medications differ, including their mechanisms, weight management evidence, side effects, dosing and available prescription products.
One of the main differences in the Tirzepatide vs Semaglutide comparison is their mechanism of action. Tirzepatide targets both GIP and GLP-1 receptors, while semaglutide targets the GLP-1 receptor.
No. Tirzepatide and semaglutide are different prescription medications. Although both are incretin-based treatments, they target different receptor pathways and are available as different prescription products.
Weight loss is an important part of the Tirzepatide vs Semaglutide comparison because both medications have been studied for weight management in specific populations. Results should be interpreted according to factors such as study design, dose, treatment duration and the population evaluated.
The medications can share gastrointestinal side effects, including nausea, diarrhea, vomiting and constipation. However, warnings, risks and reported frequencies can vary depending on the specific medication and prescription product.
Tirzepatide acts as a GIP and GLP-1 receptor agonist, whereas semaglutide is a GLP-1 receptor agonist. This difference in receptor activity is one of the central distinctions between the two medications.
Injectable tirzepatide products use once-weekly dosing. Semaglutide is available in different formulations, so its administration schedule depends on the specific prescription product.
Tirzepatide is used in prescription products including Mounjaro and Zepbound. Semaglutide is used in products including Ozempic, Wegovy and Rybelsus. Approved uses and prescribing instructions are specific to each product.
A Tirzepatide vs Semaglutide comparison can consider approved indications, mechanism of action, clinical evidence, dosing, potential side effects and cost. Individual treatment decisions should be discussed with a qualified healthcare professional.
This FAQ provides general educational information and does not replace advice from a qualified healthcare professional.
This comparison draws on peer-reviewed clinical research examining tirzepatide, semaglutide and incretin-based therapies, including head-to-head and weight-management studies.
GLP Versus provides general educational information only. The content on this page is not medical advice and should not be used to diagnose, treat or prevent a medical condition, or as a substitute for advice from a qualified healthcare professional. Prescription medications should only be used as directed by an appropriately licensed healthcare professional.